**Author Information** An event is serious (based on the ICH definition) when the patient outcome is:\* death\* life-threatening\* hospitalisation\* disability\* congenital anomaly\* other medically important event

A 17-year-old boy developed increased liver function tests during antibiotic therapy with piperacillin/tazobactam.

The boy, who had no medical history, presented to hospital with complaints of a sore throat, anorexia, pyrexia and cough for 6 days. Multiple investigations were performed, and he started receiving antimicrobial coverage with amoxicillin/clavulanic acid the day of admission, while test results were awaited. Later, on day 2 of admission, the results of his nose and throat swabs returned positive for SARS-CoV-2; further analyses suggested haemophagocytic lymphohistiocytosis (HLH). Therefore, he started receiving off-label therapy with anakinra 100 mg/day along with a 2-day course of IV immune globulin \[immunoglobulin\]. Meanwhile, antimicrobial coverage was escalated to IV piperacillin/tazobactam 4.5g three times a day on day 2 of admission, to provide cover for neutropenic sepsis. However, he subsequently exhibited increased liver function tests. After 5 days of piperacillin/tazobactam, he started receiving meropenem, since his liver function tests did not stabilise, and it was believed that piperacillin/tazobactam might have been contributing to the same \[*time to reaction onset not stated*\].

The boy\'s antibiotic therapy was discontinued after completing a total course of 7 days. He responded well to anakinra and became apyrexial 24 hours after receiving anakinra. His liver function tests, which worsened over the first 5 days (with ALT peaking at 771 U/L), reduced thereafter. Anakinra was discontinued following improvement in laboratory parameters on day 9 of admission. He was discharged on day 11, in a fit and fine condition, with normal clotting and liver function tests.
